I don't expect AGN to continue to pursue apaziquone with SPPI in future trials, as they already modified the contract once to decrease their role and duties in the partnerships. But we'll have to wait for confirmation.
Opinions and comments may have been previously posted @BioDueDiligence, at www.biotechduediligence.com, or disseminated to Chimera Research Group subscribers.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.